Adam Lenkowsky

Adam Lenkowsky is executive vice president, chief commercialization officer (CCO) at Bristol Myers Squibb. In this role, Adam leads the worldwide Commercial and Medical organizations and is responsible for driving growth across the company’s key franchises.

Prior to becoming CCO, Adam was Head of Major Markets, where he oversaw the commercialization business across 19 international markets, including Japan, Germany, U.K., and France.

Adam also served as General Manager, U.S. Commercialization, overseeing Cardiovascular, Immunology and Oncology Commercialization at Bristol Myers Squibb. The organization contributed more than one-third of the company’s total revenue in 2022 exceeding $18B.

Adam is passionate about cultivating a diverse and inclusive culture that prioritizes its people, performance, customers and, above all else, patients. He is an experienced leader who has held numerous senior strategic and operational roles across the company. He led the company’s U.S. Oncology business and the Worldwide Oncology Commercialization organization, overseeing the launch of Opdivo and Yervoy, which now generates over $10B annually and are widely recognized as two of the most successfully launched oncology products. Adam was instrumental in designing and creating the company’s Integrated Oncology operating model to drive speed and success for marketed and pipeline oncology assets.

Adam’s biopharma career extends more than 25 years across marketing, market access, sales and operations. He has held a number of key commercial leadership positions at Bristol Myers Squibb.